Company Watch

Lupin receives US FDA Approval for Suprax

Our News Bureau - Mumbai

The USFDA has approved Lupin's application for Suprax Cefixime for oral suspension 200mg/5ml. The formulation of Suprax is a line extension of Lupin's anti-infective brand Suprax Cefixime for oral suspension 100mg/5ml. The higher concentration formulation will allow parents to administer fewer teaspoons per dose of the antibiotic to their children. "The approval of our Cefixime for oral suspension 200mg/5ml product enables the launch of this important line extension to our brand Suprax in the US and allows us to increase our share of the cephalosporin oral suspension pediatric market. This market is currently valued at $625 million (as per IMS, Dec 2006). The incidence of respiratory infections is high in children and physicians need products that offer greater patient convenience and compliance," said Dr Kamal Sharma, Managing Director, Lupin.